Hi,
moomoo ID:NaN
Log Out
ENGLISH
  • ENGLISH
  • 中文繁体
  • 中文简体
donwloadimg

Download App

Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data

ZNTL Zentalis Pharmaceuticals

22.200
-0.010-0.05%
Close 10/04 16:00 ET
High
23.120
Open
22.360
Turnover
13.93M
Low
21.730
Pre Close
22.210
Volume
629.08K
Market Cap
1.27B
P/E(TTM)
Loss
52wk High
87.190
Shares
56.98M
P/E(Static)
Loss
52wk Low
17.330
Float Cap
893.53M
Bid/Ask %
0.00%
Historical High
87.190
Shs Float
40.25M
Volume Ratio
1.02
Historical Low
17.330
Dividend TTM
--
Div Yield TTM
--
P/B
2.68
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
1.56%
Amplitude
6.26%
Avg Price
22.144
Lot Size
1
Float Cap
893.53M
Bid/Ask %
0.00%
Historical High
87.190
Shs Float
40.25M
Volume Ratio
1.02
Historical Low
17.330
Dividend TTM
--
P/B
2.68
Dividend LFY
--
Turnover Ratio
1.56%
Amplitude
6.26%
Avg Price
22.144
Lot Size
1
Price Forecast

No Data

News

Comment

Company Overview More
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. It develops a broad pipeline of product candidates with an initial focus on validated oncology targets with the potential to address large patient populations. Its lead product candidate, ZN-c5, is an oral selective estrogen receptor degrader (SERD) for the treatment of estrogen receptor positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) advanced or metastatic breast cancer. The company was founded by Kevin D. Bunker on December 23, 2014 and is headquartered in New York, NY.
CEO: Dr. Kimberly Blackwell, M.D.
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...